Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO…
As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up Additional data demonstrated improved preservation of…